<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03416231</url>
  </required_header>
  <id_info>
    <org_study_id>APTN-ANSCLC-2017-001</org_study_id>
    <nct_id>NCT03416231</nct_id>
  </id_info>
  <brief_title>Apatinib Plus Docetaxel in Advanced Non-squamous Non-small Cell Lung Cancer(NSCLC)</brief_title>
  <official_title>A Study of Combined Treatment of Apatinib With Docetaxel as Post Second-line Therapy in Advanced Non-squamous Non-small Cell Lung Cancer(NSCLC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Afﬁliated Hospital of North Sichuan Medical College</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Afﬁliated Hospital of North Sichuan Medical College</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study was to evaluate the effectiveness and safety of apatinib combined
      with docetaxel in NSCLC.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 30, 2016</start_date>
  <completion_date type="Anticipated">January 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>objective response rate (ORR)</measure>
    <time_frame>6 month</time_frame>
    <description>Proportion of patients with reduction in tumor burden of a predefined amount</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>progression free survival (PFS)</measure>
    <time_frame>12 month</time_frame>
    <description>The length of time during and after the treatment of a disease, such as cancer, that a patient lives with the disease but it does not get worse.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>disease control rate (DCR)</measure>
    <time_frame>6 month</time_frame>
    <description>Disease Control Rate (DCR) and Clinical Benefit Rate (CBR) are defined as the percentage of patients with advanced or metastatic cancer who have achieved complete response, partial response and stable disease to a therapeutic intervention in clinical trials of anticancer agents.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>6-month overall survival rate</measure>
    <time_frame>6 month</time_frame>
    <description>6-month overall survival rate</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>NSCLC</condition>
  <arm_group>
    <arm_group_label>apatinib plus docetaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>apatinib combine with docetaxel， 4~6 cycles</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apatinib</intervention_name>
    <description>apatinib, at a dose of 250 mg daily,Treatment was continued until disease progression.</description>
    <arm_group_label>apatinib plus docetaxel</arm_group_label>
    <other_name>Aitan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>Docetaxel, at a dose of 75mg/m2 on days 1 and 22, repeat every 4 weeks for 4~6 cycles.</description>
    <arm_group_label>apatinib plus docetaxel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1. Male or female patients, age: ≥ 18 years of age;

          -  2. Pathologically diagnosed late (stage IIIB, stage IV, see Annex 1) non-squamous
             non-small cell lung cancer with measurable lesions (CT scan of tumor lesion longer
             than 10 mm in diameter, shorter than 15 CT scan of lymph nodes mm, the scanning layer
             thickness is not more than 5 mm;

          -  3. Previous drug treatment consisted of a platinum-based chemotherapy regimen (&gt; 1
             chemotherapy regimen) for relapse or failure of treatment.

          -  4. The main organs function properly, that is, within 14 days prior to the relevant
             indicators meet the following requirements:(1) a. Hemoglobin (HB) ≥90 g / L; (no blood
             transfusion within 14 days):b. neutrophil count (ANC) ≥ 1.5 × 109 / L; c. Platelet
             count (PLT) ≥80 × 109 / L;(2) biochemical tests to meet the following criteria:a.
             Total bilirubin (TBIL) &lt;1.5?ULN (upper limit of normal);b. Blood alanine
             aminotransferase (ALT) and aspartate aminotransferase (AST).

             5. Sign the inform consent form with good compliance.

        Exclusion Criteria:

          -  1. Squamous cell carcinoma (including adenosquamous carcinoma); Small cell lung
             carcinoma (including small cell carcinoma and non-small cell mixed lung carcinoma)

          -  2. Patients who had previously received docetaxel treatment were excluded

          -  3. Patients with active brain metastasis, carcinomatous meningitis, or spinal
             compression, or disease of brain or pia mater according to the screening test,
             imaging, CT or MRI tests (patients who have completed the treatment and in a stable
             condition 21 days before screening could be included, but brain MRI, CT or venography
             is required to confirm that there are no brain hemorrhage symptoms).

          -  4. Patients with uncontrollable hypertension (systolic blood pressure&gt; 140 mmHg,
             diastolic blood pressure&gt; 90 mmHg, despite optimal drug therapy).

          -  5. Patients with with grade Ⅱ myocardial ischemia or myocardial infarction, poor
             control of arrhythmias (including QTc interval male ≥ 450 ms, female ≥470 ms).

          -  6. According to NYHA standard, grade Ⅲ ~ Ⅳ heart failure, or cardiac color Doppler
             ultrasound examination showed left ventricular ejection fraction (LVEF) &lt;50%.

          -  7. Coagulation dysfunction (INR&gt; 1.5, PT&gt; ULN +4s or APTT&gt; 1.5 ULN), with bleeding
             tendency or ongoing thrombolysis or anti-blood coagulation treatment.

          -  8. Patients treated with anticoagulation agents or Vitamin K antagonist such as
             Warfarin, heparin, or other similar drugs.

          -  9. Patients who had obvious hemoptysis within 2 months before screening, or
             experienced daily hemoptysis with a volume more than half a tea spoon (2.5ml) or
             above.

          -  10. Patients who experienced bleeding symptoms of clinical significance within 3
             months before screening, or with confirmed bleeding tendency such as hemorrhage of
             digestive tract, hemorrhagic gastric ulcer, baseline occult blood in stool ++ and
             above, or vasculitis, etc.

          -  11. Patients who manifested arterial/venous thrombus events, e.g. cerebrovascular
             accident (including transient ischemic attack), deep venous thrombosis and pulmonary
             embolism, etc., within 12 months before screening.

          -  12. Known genetic or acquired bleeding or bleeding tendency (such as hemophilia, blood
             coagulation dysfunction, thrombocytopenia, and hypersplenism, etc.).

          -  13. Patients who have unhealed wounds or fractures for a long time.

          -  14. Patients who received major surgical operations or experienced severe traumatic
             injuries, bone fracture, or ulcers within 4 weeks before screening.

          -  15. Patients with obvious factors affecting absorption of oral drugs, such as
             difficulties in swallowing, chronic diarrhea and intestinal obstruction, etc.

          -  16. Occurrence of abdominal fistula, gastrointestinal perforation, or intraperitoneal
             abscess within 6 months before screening.

          -  17. Patients whose routine urine tests indicate that urine protein ≥ ++ or verifies
             that the 24-h urine protein quantitation ≥ 1.0 g.

          -  18. Patients with active hepatitis B virus or hepatitis c virus infection.

          -  19. Active infection requiring antimicrobial treatment, such as antibacterial,
             antifungal, or antiviral therapy.

          -  20. Patients with clinical symptoms, or dropsy of serous cavity requiring surgical
             treatment (including hydrothorax, ascites, and hydropericardium).

          -  21. Patients who have a history of psychotropic drug abuse and are unable to break the
             habit, or who have a psychogeny.

          -  22. Patients who have taken part in other drug clinical tests within 4 weeks before
             screening.

          -  23. Prior VEGFR inhibitor treatment.

          -  24. Patients who formerly suffered from or currently are complicated with other
             uncured malignant tumors, except basal cell carcinoma, carcinoma in situ of cervix and
             superficial bladder cancer that have been cured.

          -  25. Patients who received the treatment with potent CYP3A4 inhibitors within 7 days
             before screening, or potent CYP3A4 inducers within 12 days before being included.

          -  26. Pregnant or lactating women, fertile patients who are unwilling or unable to take
             effective contraceptive measures.

          -  27. Conditions determined by investigators to possibly affect the clinical study or
             determination of the study results.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daiyuan Ma, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Afﬁliated Hospital of North Sichuan Medical College</affiliation>
  </overall_official>
  <overall_official>
    <last_name>xin hu, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Nanchong Central Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>xiangdong fang, M.d.</last_name>
    <role>Study Director</role>
    <affiliation>Dazhou Central Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Daiyuan Ma, M.D</last_name>
    <phone>868172246171</phone>
    <email>angenpn@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Affiliated Hospital of North Sichuan Medical College</name>
      <address>
        <city>Nanchong</city>
        <state>Sichuan</state>
        <zip>600000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daiyuan Ma, M.D</last_name>
      <phone>868172246171</phone>
      <email>angenpn@gmail.com</email>
    </contact>
    <investigator>
      <last_name>xin hu, M.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>xiangdong fang, M.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 24, 2018</study_first_submitted>
  <study_first_submitted_qc>January 24, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 31, 2018</study_first_posted>
  <last_update_submitted>January 24, 2018</last_update_submitted>
  <last_update_submitted_qc>January 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 31, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>apatinib</keyword>
  <keyword>Docetaxel</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

